#628 P.04/0

OCT 1 4 1989

X992612

## 510(k) Summary of Safety and Effectiveness

1 513 786 7134

Submitter

Ethicon Endo-Surgery, Inc.

4545 Creek Road

Cincinnati, Ohio 45242

Contact

Edwin O. Billips

Date

August 2, 1999

Device Name

The Classification Name of this device is Manual Surgical Instrument; the Common Name is Knot Tying Instrument; and the Trade/Proprietary Name is ENDOPATH<sup>®</sup> Endoscopic Tissue Fastening System (ETFS) with Coated VICRYL<sup>®</sup>.

Predicate Device

Ethicon Endo-Surgery's ENDOPATH® Endoscopic Tissue Fastening System (ETFS)-K980022; Ethicon Endo-Surgery's ENDOPATH® Endoscopic Tissue Fastening System (ETFS)-K972679.

Device Description

The ENDOPATH<sup>©</sup> Endoscopic Tissue Fastening System (ETFS) with Coated VICRYL<sup>©</sup> is a single patient use reloadable instrument that is intended for the use in minimally invasive surgical applications where soft tissue is being approximate with interrupted stitches. It is designed for use with a 5 mm trocar. The instrument is design for eight-knot deployments.

Intended use

The ENDOPATH<sup>®</sup> Endoscopic Tissue Fastening System (ETFS) with Coated VICRYL<sup>®</sup> is intended for use in minimally invasive surgical applications where soft tissue is being approximate with interrupted stitches.

Continued on next page

## 510(k) Summary of Safety and Effectiveness,

# Technological characteristics

The technological characteristics of the New Device are the same as those of the Predicate Devices. The ENDOPATH<sup>®</sup> Endoscopic Tissue Fastening System (ETFS) with Coated VICRYL<sup>®</sup> utilizes an absorbable suture to approximate soft tissue with interrupted stitches.

### Performance data

Pre-clinical laboratory evaluations were performed to ensure that the device performs as intended. The bench data and the animal studies demonstrated that the ENDOPATH<sup>®</sup> Endoscopic Tissue Fastening System (ETFS) with Coated VICRYL<sup>®</sup> facilitated laparoscopic suturing, allowed one-handed knot deployment, and provided a secured knot in soft tissue with interrupted stitches.

#### Conclusion

Based on (21 CFR §807) and the information provided herein, we conclude that the New Device is as safe, as effective, and performs as well as the legally marketed device.





OCT 1 4 1999

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Mr. Edwin O. Billips, RAC Senior Associate, Regulatory Affairs Ethicon Endo-Surgery, Inc. 4545 Creek Road Cincinnati, Ohio 45242-2839

Re:

K992612

Trade Name: Endopath Endoscopic Tissue Fastening System with coated VICRYL®

Regulatory Class: II Product Code: GCJ Dated: August 2, 1999 Received: August 4, 1999

Dear Mr. Billips:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosures) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4595. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".

Sincerely yours

Celia M. Witten, Ph.D., M.D.

Director

Division of General and

Restorative Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosurcs

(Optional Format 1

			Page	e_1_of_1	
510(k) Number	(if known):K99261	2			
Device Name:	ENDOPATH Endosco	opic Tissue Fas	stening System	(ETFS) with C	oa
Indications For	Use:		· ·		
		•			•
The ENDOPATH <sup>®</sup> End s intended for use in min pproximated with inter	inimally invasive sur	ning System (ETI gical applications	FS) with Coated V where soft tissuc	/ICRYL® is being	
	•				
		· .			
	•	·			
	•				
		•			
	•				
(DI CACE DO A	IOT WRITE BELOV	ATUIC LINE CA	DATEM ON A	NOTICE DAG	
NEEDED)	IOT WRITE BELOV	V THIS LINE-CO	DATINUE ON A	NOTHER PAG	<b>J</b> .
	Concurrence of CD	RH, Office of De	evice Evaluation	Y(ODE)	
		(Division Sign		)	•
		Division of Ge 510(k) Numbe	neral Restorative D	evices 149261	2
• • • • • • • • • • • • • • • • • • • •		00	,	<del>-</del>	
Prescription US (Per 21 CFR 80		- OR	Over-The-C	Counter Use	